SUCCESSOR-1
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
What's the purpose of the trial?
The goal of this clinical trial is to learn more about the safety and effectiveness of investigational drug mezigdomide given in combination with Bortezomib and Dexamethasone. Researchers will compare this investigational combination against standard of care treatments Pomalidomide, Bortezomib and Dexamethasone to learn more about how mezigdomide works in relapsed or refractory multiple myeloma.
Accepting patients
Participating Centers
There are 34 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Bortezomib
- Dexamethasone
- Mezigdomide
- Pomalidomide
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.